Research on P2Y12 Platelet Inhibitors Described by Researchers at University of Chicago (Abstract Number - 98: Intravenous dose-adjusted cangrelor use for neuroendovascular procedures: An institutional experience).

According to news reporting out of the University of Chicago by NewsRx editors, research stated, "The optimal antiplatelet therapy regimen for certain neuroendovascular procedures remains unclear. Keywords: Cangrelor Therapy; Drugs and Therapies; Health and Medicine; Hemorrhage; P2Y12 Platelet Inhibitors; P2Y12 Receptor Antagonists; Pharmaceuticals EN Cangrelor Therapy Drugs and Therapies Health and Medicine Hemorrhage P2Y12 Platelet Inhibitors P2Y12 Receptor Antagonists Pharmaceuticals 1943 1943 1 03/27/23 20230330 NES 230330 2023 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Fresh data on P2Y12 platelet inhibitors are presented in a new report. [Extracted from the article]